ONWARD Medical: New Shares Listed on Euronext Following Private Placement Closure
ONWARD Medical announced on Monday the closure of its private placement with institutional investors. The new shares from this operation are now admitted for trading on the regulated markets of Euronext.
Completion of Private Placement and Listing on Euronext
The neurotechnology company ONWARD Medical has completed its previously announced private placement. Starting Monday, the new shares from this operation are admitted for trading and exchange on Euronext Brussels, Euronext Amsterdam, and Euronext Paris.
ONWARD Medical: A Leader in Neurotechnology
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
ONWARD Medical positions itself as a leading company in neurotechnology, pioneering the development of therapies designed to restore movement, function, and independence in individuals suffering from spinal cord injuries and other movement disorders. The company has developed its proprietary ARC Therapy, based on decades of scientific research and clinical studies. Its ARC-EX® system is authorized for commercial sale in the United States and Europe. ONWARD Medical is also developing an investigational implantable system called ARC-IM®, designed to address several unmet needs including blood pressure instability post-spinal injury, and can be integrated with a brain-computer interface and artificial intelligence to restore thought-controlled movement. The company is headquartered in the Netherlands, with a science and engineering center in Switzerland and an office in Boston, Massachusetts, USA.
“We continued to deliver strong commercial execution in Q3, and we achieved several meaningful scientific and regulatory milestones across our technology platforms.”
Commercial traction forte avec 40 systèmes ARC-EX vendus en Q3 et disponibilité dans plus de 60 cliniques US; CE Mark pour l'UE et clearance FDA pour usage à domicile élargissent l'opportunité commerciale; IDE approuvé pour ARC-IM permettant le lancement de l'étude pivot Empower BP; publications scientifiques majeures renforcent le dossier clinique.
Risks mentioned
retards dans les autorisations réglementaires
variations de la demande commerciale
concurrence technologique et concurrentielle
incertitudes liées aux études cliniques et résultats futurs
Opportunities identified
FDA clearance for home use expands US market opportunity
CE Mark enables commercialization in EU and facilitates entry to UK and Switzerland
IDE approval for ARC-IM enables initiation of Empower BP pivotal study
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
